Drug Trial Radar · NCT05512377
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
99
Actual
Start
Dec 13, 2022
Primary completion
Sep 25, 2025
Study completion Sep 25, 2025
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Aug 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists. The purpose of this study is to find out whether a medicine called BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder. BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. All participants take BI 907828 as a tablet once every 3 weeks. Participants may continue to take BI 907828 as long as they benefit from treatment and can tolerate it. They visit the study site regularly. At the study site, doctors regularly check the size of the tumour and whether it has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Pancreatic Neoplasms
- Solid Tumors
- Biliary Tract Cancer
- Lung Neoplasms
- Bladder Cancer
Interventions
BrigimadlinDrug
Patients received brigimadlin 45 mg orally on Day 1 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response (OR)Time frame: From the date of treatment start until the earliest date of disease progression according to RECIST version 1.1 or death. Up to 25.0 months.
Locations
60 sites in 16 countries. Site status is shown where the registry gives one.
Southern Cancer Center
Mobile, Alabama
University of Arizona
Tucson, Arizona
University of Southern California
Los Angeles, California
Stanford Cancer Institute
Palo Alto, California
Providence Medical Foundation-Santa Rosa -69764
Santa Rosa, California
Rocky Mountain Cancer Centers-Lone Tree-69498
Lone Tree, Colorado
Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
Washington D.C., District of Columbia
Norton Cancer Institute, Downtown
Louisville, Kentucky
University of Michigan
Ann Arbor, Michigan
Nebraska Cancer Specialists-Omaha-69066
Omaha, Nebraska
Perlmutter Cancer Center at NYU Langone Hospital - Long Island
Mineola, New York
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Cleveland Clinic
Cleveland, Ohio
Oncology Associates of Oregon, PC
Eugene, Oregon
Oregon Health and Sciences University
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
The University of Texas MD Anderson Cancer Center
Houston, Texas
Prince of Wales Hospital-Randwick-66496
Randwick, New South Wales, Australia
ICON-South Brisbane-69267
South Brisbane, Queensland, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Austin Health
Heidelberg, Victoria, Australia
Ordensklinikum Linz GmbH - Barmherzige Schwestern
Linz, Austria
LK Wiener Neustadt
Wiener Neustadt, Austria
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
CTR Georges-François Leclerc
Dijon, France
Institut Gustave Roussy
Villejuif, France
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, Germany
Krankenhaus Nordwest, Frankfurt
Frankfurt, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Klinikum der Universität München AÖR
München, Germany
Universitätsklinikum Ulm
Ulm, Germany
National Cancer Center Hospital East
Chiba, Kashiwa, Japan
Kanagawa Cancer Center
Kanagawa, Yokohama, Japan
Tohoku University Hospital
Miyagi, Sendai, Japan
Osaka International Cancer Institute
Osaka, Osaka, Japan
National Cancer Center Hospital
Tokyo, Chuo-ku, Japan
Japanese Foundation for Cancer Research
Tokyo, Koto-ku, Japan
Yamaguchi University Hospital
Yamaguchi, Ube, Japan
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.